CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin
In June 2020, CNS’ lead drug candidate, Berubicin, received Orphan Drug designation from the FDA. In June 2021, it received…